
Muscarinic M4 selective agonist shows promise in schizophrenia
Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia. NBI-‘568 is the first investigational, oral, muscarinic M4 selective agonist in development for this indication. The NBI-‘568-SCZ2028 dose-finding study met its primary endpoint for… Read More
